Next Generation News and Research

RSS

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

When a patient has a disease that can't be treated effectively, the physician can see clearly where research is needed.

15 Dec 2009

Safe Life increases production of its A400 Series respirators

Safe Life Corp., an innovative antimicrobial company dedicated to developing novel technologies that prevent the spread of infection and disease, announced today that it is ramping production of its comfortable, breathable, A400 Series respirator to help healthcare providers and government agencies address the global shortage of N95 respirators during the H1N1 pandemic.

15 Dec 2009

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it has signed an exclusive license and commercialization agreement with Mayo Clinic to further develop and commercialize a suite of technologies invented by a team of Mayo physicians and scientists, headed by Michael O'Connor, PhD.

15 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

US journal identifies fundamental factors behind failed EPR projects

Large-scale electronic patient record (EPR) programmes promise much but sometimes deliver little, according to a new study by UCL researchers that reviewed findings from hundreds of previous studies from all over the world.

14 Dec 2009

University of Maryland School of Nursing to spearhead new Center for Pain Studies

The University of Maryland School of Nursing in Baltimore is "uniquely poised" to spearhead a new collaborative Center for Pain Studies funded by a $2.4 million, five-year federal grant, said Susan Dorsey, PhD, RN, director of the center.

11 Dec 2009

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising.

11 Dec 2009

AFP examines insecticide resistance's effect on malaria fight in Nigeria

Agence France-Presse examines the increase in insecticide-resistant mosquitoes in Nigeria - "the latest threat to combating malaria" in the country. "Nigeria, Africa's most populous country, contributes more than a quarter of the one million malaria deaths in Africa, according to official statistics," AFP writes.

10 Dec 2009

Order Online Drugs announces the launch of OrderOnlineDrugs.com

Order Online Drugs Inc. is proud to announce the launch of OrderOnlineDrugs.com (www.orderonlinedrugs.com), a next generation online Canadian pharmacy that offers brand name prescription drugs at significantly lower prices compared to local drug stores.

10 Dec 2009

Waters begins shipping its ground-breaking SYNAPT G2 Mass Spectrometer

Waters Corporation announced today that it has shipped the first units of its ground-breaking SYNAPT(TM) G2 Mass Spectrometer, first introduced at the 2009 American Society of Mass Spectrometry (ASMS) annual conference in Philadelphia in June.

9 Dec 2009

CIDR utilizes Isilon scale-out NAS for genotyping and statistical genetics services

Isilon Systems today announced that the Center for Inherited Disease Research (CIDR) at Johns Hopkins University is using Isilon scale-out NAS to power its leading-edge genotyping and statistical genetics services, which generate up to three terabytes of new data per day.

9 Dec 2009

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

8 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Market for personalized medicine in the United States to grow 11 percent annually, shows report

The market for personalized medicine in the United States is already $232 billion, and it is projected to grow 11 percent annually, according to a new report published today by PricewaterhouseCoopers LLP, entitled The Science of Personalized Medicine: Translating the Promise into Practice.

8 Dec 2009

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

From BD (Becton, Dickinson and Company) 8 Dec 2009

ATS Medical's ATS 3f Enable Aortic Bioprosthesis receives European CE Mark approval

ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced it has received CE Mark approval to distribute the ATS 3f Enable® Aortic Bioprosthesis in the European Union, indicating it is compliant with relevant European health, safety, and environmental protection legislation.

7 Dec 2009

SU2C awards $9.68 million to support high-risk cancer research

Stand Up To Cancer (SU2C) announced today that it is awarding $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists.

7 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

The Multiple Myeloma Research Consortium (MMRC) today announced that it has awarded the Dana-Farber Cancer Institute, and its clinical researchers, Kenneth Anderson, MD, and Paul Richardson, MD, with the 2009 MMRC Center of the Year Award.

5 Dec 2009

New data from PharmAthene's anthrax vaccine program presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C.

5 Dec 2009

Next Generation News and Research

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

Safe Life increases production of its A400 Series respirators

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Molecular Partners closes its CHF 46 million Series B equity investment round

US journal identifies fundamental factors behind failed EPR projects

University of Maryland School of Nursing to spearhead new Center for Pain Studies

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

AFP examines insecticide resistance's effect on malaria fight in Nigeria

Order Online Drugs announces the launch of OrderOnlineDrugs.com

Waters begins shipping its ground-breaking SYNAPT G2 Mass Spectrometer

CIDR utilizes Isilon scale-out NAS for genotyping and statistical genetics services

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

Specialty pharmaceutical market: Treatment patterns and product performance

Market for personalized medicine in the United States to grow 11 percent annually, shows report

BD Diagnostics receives FDA clearance on Amplified DNA Assays

ATS Medical's ATS 3f Enable Aortic Bioprosthesis receives European CE Mark approval

SU2C awards $9.68 million to support high-risk cancer research

Albert Einstein College of Medicine receives SU2C grant for cancer research

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

New data from PharmAthene's anthrax vaccine program presented

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News